EQS-News: DEFENCE TO APPLY ITS PROPRIATRY ACCUMTM TECHNOLOGY IN THE DESIGN OF MESSENGER RNA ANTI-CANCER VACCINES  

CSE: DTC           FSE: DTC           USOTC: DTCFF           PRESS RELEASE

mRNA PROGRAM:

DEFENCE TO APPLY ITS PROPRIATRY ACCUM^TM TECHNOLOGY IN THE DESIGN OF MESSENGER RNA ANTI-CANCER VACCINES

Vancouver, BC, Canada, October 31^st, 2022 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is initiating a new research and development program designed to exploit the Accum^TM technology in engineering messenger (m)RNA vaccines targeting cancer. Accum^TM is designed for intracellular accumulation with capabilities to deliver an increased drug delivery to the targeted cells.

According to Precedence Research, the mRNA therapeutics market size is projected to surpass around USD 128.14 billion by 2030 and growing at a registered CAGR of 13.03% from 2022 to 2030.

https://www.globenewswire.com/news-release/2022/09/13/2515282/0/en/mRNA-...

The use of the mRNA technology in the formulation of new vaccines has been at the center of focus for many pharmaceutical companies following the successful halting of the SARS-CoV2 pandemic by Pfizer/BioNTech and Moderna’s mRNA vaccines. This new therapeutic modality is currently facing many challenges that may impede its potency. Some of these obstacles include: i) structural complexity of some very large mRNA molecules, ii) the intrinsic instability of mRNA molecules, and more importantly, iii) mRNA sensitivity to degradation by nucleases. Although some of these challenges have been partially solved by means of chemical modification strategies, efficient intracellular delivery of mRNA still represents a major hurdle, which highlights the need of future perspectives/strategies to potentiate this promising new type of medicine.

"The use of mRNA vaccines to combat the SARS-CoV2 pandemic has definitely sparked a major line of interest in the use of this technology for other diseases such as cancer. The success of these mRNA anti-cancer vaccines relies primarily on their ability to escape endosomes to reach the cytoplasm of the cell where the final protein product is generated", says Mr. Plouffe, the CEO of Defence Therapeutics.

With its impressive pre-clinical success on protein- and antibody-based drugs/vaccines, Defence Therapeutics now intends to incorporate its versatile Accum^TM technology in the design of anti-cancer vaccines. Defence and its scientific team see that the application of Accum^TM makes perfect sense as this platform is specially designed to overcome one "global and limiting step" for any molecular biopharmaceutical: endosomal escape.

"By linking Accum^TM to an mRNA molecule, we can ensure that the vaccine is not only delivered to the right cellular compartment, but also accumulates in large amounts to prime an immune response that is at least 50-100-fold higher than standard naked RNA molecules", adds Mr. Plouffe.

The Defence team recently initiated an Accum-mRNA anti-cancer vaccine program targeting solid lymphoma. When completed, the company intends to share its successful story with all major players in the field as it believes that the technology should be exploited in every mRNA vaccine currently in development by the pharmaceutical industry.

About Defence:

Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM^TM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

For further information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

[email protected]

www.defencetherapeutics.com

Cautionary Statement Regarding “Forward-Looking” Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.